Disorder of pharynx

This study compares a reduced dose of radiation therapy combined with the immunotherapy drug nivolumab against the standard treatment of full-dose radiation plus cisplatin for early-stage HPV-positive oropharyngeal cancer in non-smokers. About 384 participants are enrolled to see…

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…

This phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen sh…

This study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …

This phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…

This study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…

This phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…

This phase 2 trial tests whether combining an HPV vaccine (PRGN-2009) with the immunotherapy drug pembrolizumab can strengthen the immune system's attack on HPV-positive oropharyngeal cancer before standard treatment. Sixteen adults with newly diagnosed, HPV-related throat cancer…

This phase II trial tests whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink tumors in people with advanced nasopharyngeal carcinoma (NPC) linked to the Epstein-Barr virus. About 113 patients with recurrent or metastatic NPC that can't be cured will r…

This early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study looks at whether giving lower doses of radiation to a smaller area after robotic surgery can still keep HPV-positive throat cancer from coming back. About 150 adults with early-stage throat cancer will receive this gentler radiation plan. The goal is to see if two year…

This phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…

This study tests whether adding the targeted therapy cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) can better control advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy an…

This study tests whether using MRI scans to plan radiation doses can control HPV-positive throat cancer as well as standard treatment, while reducing severe swallowing side effects. About 90 adults with early-stage cancer will receive radiation doses adjusted based on MRI images.…

This study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…

This study is testing whether a PET scan taken partway through radiation treatment can identify patients with HPV-related throat cancer who can safely receive a lower dose of radiation. The goal is to reduce side effects while still controlling the cancer. About 120 adults with s…

This study tests a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that has spread or returned. The goal is to see how well the treatment shrinks tumors and delays cancer growth. Participants must have a confirmed diagnosis a…

This early-phase trial studies whether a combination of regular check-ups, scans, blood tests, and ultrasound can safely find and guide removal of remaining cancer in neck lymph nodes after standard radiation for advanced nasopharyngeal cancer. About 50 adults aged 18-70 with N3 …

This study tests whether adding two drugs, niraparib and dostarlimab, to standard radiation therapy can better control advanced head and neck cancer. About 34 adults with stage III or IV cancer will receive the drugs before, during, and after radiation. The goal is to see if this…

This study tests whether giving an extra dose of radiation to oxygen-poor (hypoxic) areas of head and neck tumors can improve treatment response. About 91 adults with advanced squamous cell cancer of the throat or voice box will receive standard chemo-radiation with or without th…

This phase 2 trial is testing whether combining pembrolizumab (an immunotherapy) with olaparib (a PARP inhibitor) can shrink tumors in people with nasopharyngeal cancer that has become resistant to platinum-based chemotherapy. The study plans to enroll 30 adults whose cancer has …

This early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This phase 3 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locoregionally advanced nasopharyngeal carcinoma. About 450 participants will receive either tislelizumab plus chemo or a placebo plus ch…

This study tests whether giving radiation only to the involved lymph nodes (instead of the whole neck area) can control early-stage nasopharyngeal cancer just as well, with fewer side effects. About 414 adults with limited lymph node involvement will be randomly assigned to eithe…

This study looks at whether giving less radiation after surgery for HPV-positive throat cancer can still prevent the cancer from coming back while causing fewer long-term side effects. About 83 adults with HPV-positive oropharyngeal cancer will receive either a standard or reduce…

This study tests a drug called 177Lu-DOTATATE, which delivers radiation directly to cancer cells, in people with metastatic nasopharyngeal cancer that has not responded to at least two prior treatments. Only patients whose tumors show up on a special scan are eligible. The main g…

This phase 2 trial tests whether giving targeted radiation along with two immunotherapy drugs (evorpacept and pembrolizumab) before standard surgery can improve outcomes for people with HPV-related throat cancer. The study enrolls 29 patients with early-stage, resectable disease.…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39…

This pilot study tests a personalized radiation plan for people with HPV-related throat cancer that is considered high-risk. Using advanced scans (MRI and PET), doctors adjust the radiation dose to target the most aggressive parts of the tumor. The goal is to see if this approach…

This study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…

This phase II trial is testing whether combining an immunotherapy drug (PD-1 antibody) with standard chemotherapy and radiation can help people whose nasopharyngeal cancer has come back after initial treatment. The study includes 68 participants with high-risk recurrent cancer th…

This study tests whether giving radiation to a smaller area of the neck is as good as the standard larger area for treating nasopharyngeal cancer that hasn't spread. About 474 adults with newly diagnosed cancer will be randomly assigned to one of two radiation plans. The goal is …

This study was designed for people with HPV-positive oropharyngeal cancer who still had signs of the virus in their blood after completing standard treatment. Researchers planned to give an immunotherapy drug called BALSTILIMAB to see if it could clear the virus and improve long-…

This study tests whether different drug combinations can improve survival and reduce side effects for people with intermediate or high-risk oropharyngeal (throat) cancer. About 785 participants will receive one of several experimental treatments alongside standard chemoradiothera…

This study tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced head and neck cancer that has spread or come back. About 410 participants whose tumors have …

This phase 2 trial tests the safety and effectiveness of SKB264, a new drug, in 321 adults with advanced solid tumors, specifically non-small cell lung cancer and nasopharyngeal carcinoma. Participants receive SKB264 alone until the drug stops working or side effects become too s…

This phase II trial is testing whether combining targeted radiation (SBRT) with an immunotherapy drug (camrelizumab) and standard chemotherapy can help control nasopharyngeal cancer that has spread to a few other parts of the body. The study involves 41 participants who have not …

This study tests a less intense version of standard chemo-radiation for people with HPV-positive throat cancer who have had robotic surgery to remove visible tumors. The goal is to see if the milder treatment works just as well as the standard dose but causes fewer side effects. …

This phase 3 trial tests whether adding the experimental drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18–75 are participating. T…

This phase 2 trial tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can better prevent nasopharyngeal cancer from returning after initial treatment. About 150 patients whose cancer did not fully respond to induction chemotherapy will re…

This study tests a shorter, more intense course of radiation therapy (hypofractionated IMRT) given after surgery for head and neck cancer. The goal is to see if it is safe and if it can help patients maintain better swallowing function compared to the standard longer radiation sc…

This study tests two experimental vaccines (HB-201 and HB-202) given with standard chemotherapy drugs (carboplatin and paclitaxel) to people with HPV16-positive oropharyngeal cancer. The goal is to see if this combination can shrink tumors enough to allow less intensive follow-up…

This early-stage trial tests whether injecting a person's own muscle cells into the tongue can safely improve swallowing problems caused by cancer treatment. The study involves 18 adults who had surgery, chemo, or radiation for oropharyngeal cancer at least two years ago. Researc…

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced nasopharyngeal cancer that has not responded to at least two prior treatments. About 386 participants will be randomly assigned to receive either the new drug or a standard …

This study tests whether a vaccine (PDS0101) given alone or with an immunotherapy drug (pembrolizumab) can shrink HPV-related throat tumors before surgery. About 20 adults with advanced cancer that has spread to nearby lymph nodes will receive the treatment. The goal is to see if…

This early-phase trial tests the combination of two drugs, vorinostat and azacitidine, in people with nasopharyngeal cancer or nasal NK-T cell lymphoma that has come back or spread. The main goal is to find the safest dose and see how the body responds. Only 18 participants are e…

This study is testing whether a precise form of radiation called proton therapy can control head and neck cancer after surgery as well as standard X-ray radiation, but with fewer side effects. About 174 adults with newly diagnosed head and neck cancer will receive either proton t…

This study tests whether a much lower dose of radiation (30 Gy) combined with standard chemotherapy works as well as the usual high dose (70 Gy) for people with HPV-positive throat cancer. The goal is to reduce long-term side effects while still controlling the cancer. About 316 …

This study compares a lower dose of radiation to the standard dose for people with HPV-positive throat cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects. The trial involves 23 participants with advanced but non-sprea…

This Phase 3 trial tests whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer. About 252 participants will receive either the combination or pembrolizumab alone. T…

This phase II trial is testing whether a lower dose of chemoradiotherapy, given after initial chemotherapy, can effectively treat locally advanced HPV-positive oropharynx cancer while reducing long-term side effects. The study involves 43 participants and tracks how long the canc…

This study looks at people with HPV-positive throat cancer that has spread but can still be removed with surgery. After surgery, some patients get the usual high-dose radiation plus chemo, while others get a lower dose. The goal is to see if the lower dose works just as well and …

This study looks at whether giving a lower dose of radiation after robotic surgery can help people with HPV-positive throat cancer have fewer side effects, like trouble swallowing, while still controlling the cancer. About 33 adults with this type of cancer will receive the reduc…

This phase 2 trial compares standard treatment (radiation plus chemotherapy drug cisplatin) against two experimental arms using the immunotherapy drug durvalumab with radiation, followed by either durvalumab alone or durvalumab plus another immunotherapy, tremelimumab. The study …

This study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a ban…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This phase 3 trial compares two types of radiation therapy for advanced throat cancer: standard photon radiation (IMRT) and newer proton beam therapy (IMPT). The goal is to see if proton therapy causes fewer severe side effects while still controlling the cancer. About 440 patien…

This phase 2 trial tests a combination of two chemotherapy drugs (carboplatin and nab-paclitaxel) plus an immunotherapy drug (durvalumab) given before surgery for people with locally advanced head and neck cancer. The goal is to shrink or eliminate the tumor so that radiation—whi…

This early-phase study tests whether a personalized immune cell therapy (dendritic cells) is safe and can help control advanced nasopharyngeal cancer. The treatment uses the patient's own immune cells and donor cell secretions to boost the body's cancer fight. The study involves …

This phase 3 trial tests whether upadacitinib (Rinvoq) can help people with Takayasu arteritis, a rare disease that inflames large arteries. About 56 adults who have had a recent relapse despite steroids will receive either upadacitinib or a placebo, along with a steroid taper. T…

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This study tests a drug called MRG003 in adults whose nasopharyngeal cancer has come back or spread and hasn't responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 238 participants will receive the drug, and researchers will…

This study compares two standard treatments—radiation therapy and surgery—for people with HPV-related throat cancer. The goal is to see which approach provides better survival and quality of life. About 61 adults with early-stage cancer are taking part to help guide future treatm…

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, given before surgery, can help treat HPV-related throat cancer that can be removed. About 20 adults with stage I oropharyngeal cancer will receive two doses of atezolizumab followed by standard surgery. Th…

This early-stage trial tests whether specially trained immune cells (T cells) that are resistant to a cancer's defense protein (TGF-beta) can safely fight EBV-positive nasopharyngeal carcinoma. Fourteen patients with relapsed or hard-to-treat cancer will receive these gene-modifi…

This study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…

This phase II trial is testing a combination of three drugs—anlotinib, penpulimab, and capecitabine—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study includes 59 adults aged 18 to 65 who have not had prior systemic therapy for their re…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This study tests an oral drug called APG-157 given before standard treatment (surgery or radiation) for people with newly diagnosed head and neck cancer. The goal is to see if the drug can shrink tumors and improve outcomes. About 24 adults with early to advanced stage cancer wil…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This study tests a treatment plan for people with stage IVA nasopharyngeal cancer (a type of nose and throat cancer). Participants receive a combination of the immunotherapy drug pembrolizumab and chemotherapy before and during radiation, followed by maintenance pembrolizumab for…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This study tests if a person's own muscle cells, grown in a lab and injected into the tongue, can safely improve swallowing problems caused by head and neck cancer treatment. About 66 adults who finished cancer treatment at least 2 years ago and still have moderate swallowing tro…

This phase 2 trial tests whether adding a PD-1 inhibitor (a type of immunotherapy) to standard chemotherapy before radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. About 150 participants will receive either the combination or chemotherapy alone, f…

This phase II trial tests a personalized treatment for metastatic nasopharyngeal carcinoma. Patients first receive tislelizumab (immunotherapy) plus chemotherapy. Those who respond well may avoid or reduce radiotherapy, while others get targeted radiation. The study aims to see i…

This Phase III trial tests whether adding a low-dose chemotherapy pill (capecitabine) after standard chemoradiation helps prevent cancer from returning in people with high-risk nasopharyngeal cancer. About 252 participants with stage T1-2N1M0 disease and certain high-risk feature…

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…

This study compares two ways to remove tonsils in adults with recurrent or chronic tonsillitis: the traditional method (extracapsular) and a newer partial removal method (intracapsular). Researchers will track pain, bleeding, and painkiller use after surgery in 167 adults. The go…

This phase 3 trial tests whether using smaller radiation targets after initial chemotherapy can control advanced nasopharyngeal cancer just as well as standard larger targets, while reducing side effects. About 445 patients with stage III-IVa disease are enrolled. The study compa…

This Phase 3 trial tests whether giving a three-drug chemotherapy regimen (docetaxel, cisplatin, and fluorouracil) before radiotherapy helps people with advanced laryngeal or hypopharyngeal cancer avoid losing their voice box. The standard approach is to give cisplatin during rad…

This study is testing a blood test that looks for HPV DNA in the blood of people treated for HPV-positive oropharyngeal cancer. The goal is to see if the test can find cancer recurrence earlier than standard follow-up methods. About 150 participants are being followed after treat…

This study tests a surgical technique called tongue base mucosectomy, combined with detailed tissue analysis, to find the original site of head and neck cancers that have spread to lymph nodes but have no known primary source. About 100 patients will undergo this procedure, and r…

This study is testing whether a blood test called NavDx can find HPV-related oropharyngeal cancer early by looking for HPV DNA in the blood. Researchers are enrolling adults aged 45 and older with multiple sexual partners who have no history of this cancer. Participants give bloo…

This study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…

This study tests whether using home sensors to monitor dehydration risk can reduce hospitalizations and emergency room visits in head and neck cancer patients. About 427 participants will either use the CYCORE sensor system plus standard care, or standard care alone. The goal is …

This Phase 3 trial tests whether acupuncture can prevent dry mouth (xerostomia) in 435 head and neck cancer patients receiving radiation. Participants are split into two different acupuncture groups or a standard care group. The study compares which approach better reduces dry mo…

This study tests a propolis throat spray to see if it can reduce how often and how long healthy adults get sick. One hundred people aged 18 to 65 will use the spray or a placebo daily for 16 weeks and report any illnesses. The goal is to find a simple way to prevent common colds …

This phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. T…

This study compares standard in-person follow-up care with telemedicine (phone or video visits) for people who have finished treatment for HPV-related throat cancer and show no signs of cancer on scans. The goal is to see which approach better maintains quality of life, detects a…

This study tests whether wearing pressurized gloves and foot caps during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by the drug paclitaxel. It involves 182 people with nasopharyngeal cancer who have not yet started treatment. Each patient serves as their…

This study looks at whether people with throat cancer on one side of the neck can safely receive radiation to only that side, instead of both sides. The goal is to reduce side effects from unnecessary radiation. About 8 participants with early-stage HPV-related tonsil or tongue b…

This study planned to test a mouthwash made from copaíba oil, a natural resin, to prevent and treat painful mouth sores (oral mucositis) in people with oral cancer undergoing radiation. The trial was set to include 40 patients, half using the copaíba mouthwash and half a placebo,…

This study tests an online program called Empowered Survivor, designed to help people who have had oral or throat cancer feel more confident managing their health after treatment. Researchers are comparing it to a free online tool already available for cancer survivors. The goal …

This study is testing whether giving less radiation to the lymph nodes can reduce side effects for people with low-risk HPV-related throat cancer. The goal is to see if doctors can safely skip radiation to some lymph node areas without increasing the chance of the cancer coming b…

This study tests a procedure called RhinAer that uses heat to treat the nerves in the nose for people with chronic rhinitis (long-term stuffy or runny nose). Researchers want to see if it reduces inflammation and improves symptoms like cough and post-nasal drip. About 25 adults a…

This early-phase study tests the safety of combining the drug tolinapant with radiation therapy for people with head and neck cancer that has spread locally but hasn't been treated yet. Participants are those who cannot receive the standard chemotherapy drug cisplatin. The goal i…

This study compares two treatments for early-stage throat cancer: robotic surgery (TORS) or radiation therapy (IMRT). It looks at which one leads to better swallowing function and overall quality of life. About 138 adults with HPV-related throat cancer are taking part. The goal i…

This study compares two common surgical tools (monopolar and bipolar electrocautery) used during tonsil removal to see which one causes less pain and bleeding after surgery. It involves 74 people aged 5 to 40 who need their tonsils out due to chronic tonsillitis or other issues. …

This study tests whether a program combining resistance training and a Mediterranean diet is practical and helpful for people with head and neck cancer undergoing radiation. Forty participants will receive supervised exercise sessions and pre-made meals, plus dietary coaching. Th…

This study aimed to see if using MRI scans to guide radiation away from the main saliva ducts could reduce dry mouth in people with oropharynx cancer. The trial planned to compare standard radiation with a new approach that spares these ducts. However, the study was withdrawn bef…

This study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…

This pilot study is testing whether two natural dietary supplements—taxifolin (found in apples and onions) and ergothioneine (found in mushrooms)—can improve immune function in healthy adults aged 50 to 65. Researchers will measure how well immune cells engulf and destroy threats…

This study tests a new program designed to help head and neck cancer patients who feel depressed. The goal is to see if the program is practical and liked by patients, and if it can improve their mood and help them follow through with swallowing exercises and dental care. About 1…

This study follows 108 nasopharyngeal cancer survivors who had radiation and chemotherapy at least four years ago. Researchers are measuring long-term side effects like hormone problems, hearing loss, and memory issues using blood tests, cognitive exams, and quality-of-life surve…

This study looks at whether genetic markers (like tumor mutations and DNA in the blood) and special MRI scans can predict how well chemoradiotherapy works for patients with HPV-negative oropharyngeal cancer. Researchers will follow 30 patients to see if these tests can forecast t…

This study looks at whether a lower dose of radiation can safely treat HPV-positive oropharynx (throat) cancer in people who have never smoked or smoked very little. Researchers will follow 75 patients for up to 5 years to see if the cancer stays away and how their quality of lif…

This study looks at symptoms reported by patients with oropharyngeal cancer after they finish radiation or chemoradiation. Researchers will review medical records and have patients complete questionnaires about their symptoms. The goal is to learn more about what patients experie…

This study looks at 100 patients with recurrent hypopharyngeal cancer who had salvage surgery with flap reconstruction. Researchers compare free flaps and pedicled flaps to see which leads to fewer complications. The goal is to find the best surgical approach for these patients.

This study looks at 400 people who had surgery to remove throat cancer (laryngectomy or pharyngolaryngectomy). The goal is to find out which factors, like using a surgical flap or muscle loss (sarcopenia), increase the risk of a fistula—a leak that can cause infection. Researcher…

This study aims to see if a simple, non-invasive breathing test can accurately measure the acidity (pH) in the airways, which is often abnormal in lung diseases. Researchers will compare results from this breath test with standard methods in 150 healthy volunteers and people with…

This study looks at whether the newest version of the cancer staging system (TNM-9) accurately predicts outcomes for people with nasopharyngeal carcinoma in parts of China where the disease is less common. Researchers will review medical records from about 1,400 patients treated …

This study looks at whether a blood test that finds HPV DNA can spot throat cancer coming back after treatment, possibly earlier than usual scans. Researchers will follow 200 patients with HPV-positive oropharyngeal cancer to see how accurate the test is. The goal is to improve m…

This study is screening 1,500 adults for oral HPV infection and antibodies to build a group at higher risk for HPV-related throat cancer. Researchers will follow them over time to see which infections persist and what factors (like mouth bacteria or immune response) increase canc…